Literature DB >> 21883180

Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children.

Uri Kramer1, Ching-Shiang Chi, Kuang-Lin Lin, Nicola Specchio, Mustafa Sahin, Heather Olson, Rima Nabbout, Gerhard Kluger, Jainn-Jim Lin, Andreas van Baalen.   

Abstract

PURPOSE: To explore the correlations between treatment modalities and selected disease parameters with outcome in febrile infection-related epilepsy syndrome (FIRES), a catastrophic epileptic encephalopathy with a yet undefined etiology.
METHODS: We conducted a retrospective multicenter study on children who had been included in eight studies published between November 2001 and July 2010. Additional data were retrieved from six of the eight participating centers. KEY
FINDINGS: The 77 enrolled patients presented with prolonged refractory status epilepticus. A preceding febrile infection had been reported in 96% of them. Treatment modalities included antiepileptic drugs (a median of six), intravenous immunoglobulin (IVIG, 30 patients), steroids (29 patients), burst-suppression coma (BSC, 46 patients), and other less conventional agents. There was no evidence of efficacy for those treatment modalities except for IVIG (two patients), a ketogenic diet (one patient), and a prolonged cycle of barbiturate anesthesia coma (one patient). Nine patients (11.7%) died during the acute phase of FIRES. Only 12 of the 68 surviving patients (18%) retained normal cognitive level, but most of them had learning disabilities. Sixty-three patients (93%) had refractory epilepsy at follow-up. Cognitive levels at follow-up were significantly associated with duration of BSC (p = 0.005) and younger age at FIRES onset (p = 0.02). SIGNIFICANCE: The outcome of FIRES is poor. No therapeutic agent was efficacious in shortening the acute phase, with the possible exception of a ketogenic diet. Treatment by inducing a prolonged BSC was associated with a worse cognitive outcome. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883180     DOI: 10.1111/j.1528-1167.2011.03250.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  45 in total

1.  NORSE Versus FIRES: What's in a Name?

Authors:  Katherine Nickels
Journal:  Epilepsy Curr       Date:  2018 Sep-Oct       Impact factor: 7.500

Review 2.  Autoimmune encephalitis and its relation to infection.

Authors:  Arun Venkatesan; David R Benavides
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

Review 3.  Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).

Authors:  Carlos A Pardo; Rima Nabbout; Aristea S Galanopoulou
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

4.  Febrile infection-related epilepsy syndrome treated with anakinra.

Authors:  Daniel L Kenney-Jung; Annamaria Vezzani; Robert J Kahoud; Reghann G LaFrance-Corey; Mai-Lan Ho; Theresa Wampler Muskardin; Elaine C Wirrell; Charles L Howe; Eric T Payne
Journal:  Ann Neurol       Date:  2016-11-14       Impact factor: 10.422

Review 5.  Treating Immune-Related Epilepsy.

Authors:  Sonal Bhatia; Sarah E Schmitt
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-14       Impact factor: 5.081

6.  Revising and refining the epilepsy classification system: priorities from a developing world perspective.

Authors:  Gretchen L Birbeck
Journal:  Epilepsia       Date:  2012-07       Impact factor: 5.864

7.  Treatment of status epilepticus: an international survey of experts.

Authors:  James J Riviello; Jan Claassen; Suzette M LaRoche; Michael R Sperling; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Lori Shutter; David M Treiman; Paul M Vespa; Rodney Bell; Gretchen M Brophy
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

Review 8.  Status Epilepticus.

Authors:  Syndi Seinfeld; Howard P Goodkin; Shlomo Shinnar
Journal:  Cold Spring Harb Perspect Med       Date:  2016-03-01       Impact factor: 6.915

Review 9.  Treatment of epileptic encephalopathies.

Authors:  Amy McTague; J Helen Cross
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

Review 10.  Actual insights into the clinical management of febrile seizures.

Authors:  Mario Mastrangelo; Fabio Midulla; Corrado Moretti
Journal:  Eur J Pediatr       Date:  2014-01-30       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.